NCT03188198

Risk Adapted Therapy in Diffuse Large B Cell Lymphoma

Phase II Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R in Untreated De Novo Diffuse Large B-Cell Lymphomas

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Mansoura University · Academic / Other
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

This randomized phase II trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.

Detailed description

objectives: 1. To compare the response rates and toxicity of R-CHOP versus DA-EPOCH-R in untreated CD20+ diffuse large B-cell lymphomas. 2. To compare the event-free survival of R-CHOP versus DA-EPOCH-R chemotherapy in untreated CD20+ diffuse large B-cell lymphomas. 3. To develop predictors of outcome of R-CHOP and DA-EPOCH-R chemotherapy.

Conditions

• Large B Cell Lymphoma

Interventions

Type	Name	Description
DRUG	rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim

Timeline

• Start date: 2016-06-01
• Primary completion: 2018-06-01
• Completion: 2019-06-01
• First posted: 2017-06-15
• Last updated: 2017-07-06

Locations

1 site across 1 country: Egypt